Sonoma Biotherapeutics to Present Preclinical Data from Novel Treg Therapy for Rheumatoid Arthritis at American College of Rheumatology Convergence 2023
06 Nov 2023
Cell TherapyImmunotherapy
Dosing of first patient with SBT-77-7101 for the treatment of rheumatoid arthritis expected in early 2024
SOUTH SAN FRANCISCO, Calif. & SEATTLE--(BUSINESS WIRE)-- Sonoma BioTherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, will present preclinical data from its autologous chimeric antigen receptor (CAR) Treg therapy product candidate for the treatment of rheumatoid arthritis (RA) at the American College of Rheumatology (ACR) Convergence 2023, taking place in San Diego, California from November 10-15th.
“Our CAR-Treg product candidate, SBT-77-7101, is designed to target proteins that accumulate in the joints and blood of patients with RA,” said Mark D. Eisner, M.D., MPH, Chief Medical Officer of Sonoma Biotherapeutics. “Results from this study show that we can detect CAR-reactive citrullinated antigens in both synovial fluid and blood. In addition, these protein levels correlated with systemic markers of inflammation. The levels of these CAR-reactive citrullinated proteins and inflammatory markers will be further evaluated in our upcoming Phase 1 study of SBT-77-7101 in patients with RA, which is on track to commence in early 2024.”
Presentation Details
Title: Detection of Citrullinated Proteins Recognized by a Novel Chimeric Antigen Receptor Treg Therapy in Both Synovial Fluid and Serum from Patients with Rheumatoid Arthritis
Presenting Author: Sara Charmsaz, Ph.D.
Session Type: Poster Session A
Poster Number: 0423
Session Date/Time: Sunday, November 12 from 9:00 – 11:00 AM PT
About SBT-77-7101
SBT-77-7101 is a novel autologous chimeric antigen receptor (CAR) engineered regulatory T cell (Treg) therapy in development for the potential treatment of rheumatoid arthritis and hidradenitis suppurativa. SBT-77-7101 is designed to selectively target citrullinated proteins, which are a hallmark of many autoimmune and inflammatory diseases and are found in the inflamed disease-associated tissues of patients. Directly targeting these citrullinated proteins is intended to dampen inflammation at its source, while leveraging an autologous approach that utilizes patients’ own cells has potential to restore balance to the immune system and promote long-term immune tolerance.
About Sonoma Biotherapeutics
Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted and durable Treg cell therapies. Sonoma Biotherapeutics is based in South San Francisco and Seattle. For more information, visit sonomabio.com and follow on X, formerly Twitter, and LinkedIn.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.